一分钟看懂
这是一项关于肝细胞癌的不适用研究，登记的药物或干预包括FOLFOX4；Adebrelimab；Apatinib；Icaritin；Retlirafusp alfa；QL1706；Bevacizumab；HAIC；The original treatment regimen，当前状态为招募中。登记地点显示中国南京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
FOLFOX4；Adebrelimab；Apatinib；Icaritin；Retlirafusp alfa；QL1706；Bevacizumab；HAIC；The original treatment regimen · 不适用
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital · 南京
公开的入选条件
- 1. Age ≥18 years old, male or female
- 2. Hepatocellular carcinoma patients diagnosed by cytology or tissue puncture, or who meet clinical diagnostic criteria and cannot be treated with radical treatment (radical surgery, ablation, radiotherapy, etc.)
- 3. Clinical disease progression after first-line targeted combined immune system therapy (PD-1 or PD-L1 monoclonal antibody only)
- 4. Life expectancy exceeds 3 months
- 5. ECOG physical condition score 0\~1
- 6. Women of childbearing age must have a serum pregnancy study done within 7 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must consent to contra
- 7. Before the first dose of the investigational drug, the laboratory test values met the following conditions: ①blood routine (no blood transfusion within 14 days before screening, no hematopoietic stimulating drug correction) : white blood cell count (WBC) ≥
- 8. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06893887；登记信息更新于 2026-10-01。